IPNews® – Impax Laboratories Inc.’s attempt to bring to market a generic version of the emotional instability treatment Nuedexta drew a new infringement lawsuit on Monday from Aliso Viejo, Calif.-based Avanir Pharmaceuticals Inc., which owns the patent for Nuedexta.

Avanir’s patent for the drug issued in July, and it says Impax’s recently filed abbreviated new drug application with the U.S. Food and Drug Administration would infringe that patent. The drug is used to treat “emotional lability,” or uncontrollable emotional outbursts as a result of brain damage. To continue reading, click: OC Drug Maker Avanir Tries To Block Impax’s Generic Nuedexta